These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 16550628)
1. Therapeutic results in patients with relapsed diffuse large B cell Non-Hodgkin's lymphoma achieving complete response only after autologous stem cell transplantation. Ferrara F; Viola A; Copia C; Schiavone EM; Celentano M; Pollio F; D'Amico MR; Palmieri S Hematol Oncol; 2006 Jun; 24(2):73-7. PubMed ID: 16550628 [TBL] [Abstract][Full Text] [Related]
2. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission. Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255 [TBL] [Abstract][Full Text] [Related]
3. High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission. Papajik T; Raida L; Faber E; Vondrakova J; Prochazka V; Kubova Z; Skoumalova I; Jarosova M; M LK; Paucek B; Myslivecek M; Neoral C; Oral I; Jarkovsky J; Dusek L; Indrak K Neoplasma; 2008; 55(3):215-21. PubMed ID: 18348654 [TBL] [Abstract][Full Text] [Related]
4. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy. Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397 [TBL] [Abstract][Full Text] [Related]
5. Role of hematopoietic stem cell transplantation for advanced-stage diffuse large cell B-cell lymphoma-B. Nademanee A; Forman SJ Semin Hematol; 2006 Oct; 43(4):240-50. PubMed ID: 17027658 [TBL] [Abstract][Full Text] [Related]
6. [Autologous hematopoietic stem cell transplantation for aggressive B-cell non-Hodgkin's lymphoma]. Hirose A; Yamane T; Nakajima Y; Manabe M; Kanashima H; Hagihara K; Sakamoto E; Nakamae M; Terada Y; Kosaka S; Aoyama Y; Sakamoto C; Kumura T; Koh KR; Hirai M; Ohta K; Nakao Y; Mugitani A; Teshima H; Hino M Gan To Kagaku Ryoho; 2005 Dec; 32(13):2059-64. PubMed ID: 16352929 [TBL] [Abstract][Full Text] [Related]
7. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma]. Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686 [TBL] [Abstract][Full Text] [Related]
8. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients. Zinzani PL; Tani M; Molinari AL; Stefoni V; Zuffa E; Alinari L; Gabriele A; Bonifazi F; Salvucci M; Tura S; Baccarani M Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357 [TBL] [Abstract][Full Text] [Related]
9. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Sirvent A; Dhedin N; Michallet M; Mounier N; Faucher C; Yakoub-Agha I; Mohty M; Robin M; Tabrizi R; Clement L; Bilger K; Larosa F; Contentin N; Huyn A; François S; Bulabois CE; Ceballos P; Bourrhis JH; Buzyn A; Cornillon J; Guillerm G; de Revel T; Bay JO; Guilhot F; Milpied N Biol Blood Marrow Transplant; 2010 Jan; 16(1):78-85. PubMed ID: 19744569 [TBL] [Abstract][Full Text] [Related]
10. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961 [TBL] [Abstract][Full Text] [Related]
11. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. Mounier N; Canals C; Gisselbrecht C; Cornelissen J; Foa R; Conde E; Maertens J; Attal M; Rambaldi A; Crawley C; Luan JJ; Brune M; Wittnebel S; Cook G; van Imhoff GW; Pfreundschuh M; Sureda A; Biol Blood Marrow Transplant; 2012 May; 18(5):788-93. PubMed ID: 22005647 [TBL] [Abstract][Full Text] [Related]
12. Autologous stem-cell transplantation in patients with HIV-related lymphoma. Balsalobre P; Díez-Martín JL; Re A; Michieli M; Ribera JM; Canals C; Rosselet A; Conde E; Varela R; Cwynarski K; Gabriel I; Genet P; Guillerm G; Allione B; Ferrant A; Biron P; Espigado I; Serrano D; Sureda A J Clin Oncol; 2009 May; 27(13):2192-8. PubMed ID: 19332732 [TBL] [Abstract][Full Text] [Related]
13. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group. Arranz R; Conde E; Grande C; Mateos MV; Gandarillas M; Albo C; Lahuerta JJ; Fernández-Rañada JM; Hernández MT; Alonso N; García Vela JA; Garzón S; Rodríguez J; Caballero D; Eur J Haematol; 2008 Mar; 80(3):227-35. PubMed ID: 18088400 [TBL] [Abstract][Full Text] [Related]
14. LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre. Perz JB; Giles C; Szydlo R; O'Shea D; Sanz J; Chaidos A; Wagner S; Davis J; Loaiza S; Marin D; Apperley J; Olavarria E; Rahemtulla A; Lampert I; Naresh K; Samson D; MacDonald D; Kanfer EJ Bone Marrow Transplant; 2007 Jan; 39(1):41-7. PubMed ID: 17115062 [TBL] [Abstract][Full Text] [Related]
15. Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome. Larouche JF; Berger F; Chassagne-Clément C; Ffrench M; Callet-Bauchu E; Sebban C; Ghesquières H; Broussais-Guillaumot F; Salles G; Coiffier B J Clin Oncol; 2010 Apr; 28(12):2094-100. PubMed ID: 20308668 [TBL] [Abstract][Full Text] [Related]
16. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation. Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH; Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634 [TBL] [Abstract][Full Text] [Related]
18. Post-autologous stem cell transplantation administration of rituximab improves the outcome of patients with aggressive B cell non-Hodgkin's lymphoma. Tsirigotis P; Dray L; Resnick IB; Ackerstein A; Gesundheit B; Elad S; Or R; Shapira MY Ann Hematol; 2010 Mar; 89(3):263-72. PubMed ID: 19693502 [TBL] [Abstract][Full Text] [Related]
19. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma. Aksentijevich I; Jones RJ; Ambinder RF; Garrett-Mayer E; Flinn IW Biol Blood Marrow Transplant; 2006 Sep; 12(9):965-72. PubMed ID: 16920563 [TBL] [Abstract][Full Text] [Related]
20. High-dose chemotherapy with autologous stem cell transplantation in extranodal NK/T-cell lymphoma: a retrospective comparison with non-transplantation cases. Kim HJ; Bang SM; Lee J; Kwon HC; Suh C; Kim HJ; Lee JH; Ryoo BY; Park YH; Kwon JM; Oh SY; Lee HR; Kim K; Jung CW; Park K; Kim WS Bone Marrow Transplant; 2006 May; 37(9):819-24. PubMed ID: 16547486 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]